Xylem Inc. declares fourth quarter dividend of 21 cents per share
Get Alerts XYL Hot Sheet
Join SI Premium – FREE
RYE BROOK, N.Y.--(BUSINESS WIRE)-- The Board of Directors of Xylem Inc. (NYSE: XYL) has declared a fourth quarter dividend of $0.21 per share payable on December 7, 2018 to shareholders of record as of November 1, 2018. Xylem is a leading global water technology company focused on solving the world’s most challenging water issues.
About Xylem
Xylem (XYL) is a leading global water technology company committed to developing innovative technology solutions to the world’s water challenges. The Companyâs products and services move, treat, analyze, monitor and return water to the environment in public utility, industrial, residential and commercial building services settings. Xylem also provides a leading portfolio of smart metering, network technologies and advanced infrastructure analytics solutions for water, electric and gas utilities. The Companyâs more than 16,500 employees bring broad applications expertise with a strong focus on identifying comprehensive, sustainable solutions. Headquartered in Rye Brook, New York with 2017 revenue of $4.7 billion, Xylem does business in more than 150 countries through a number of market-leading product brands.
The name Xylem is derived from classical Greek and is the tissue that transports water in plants, highlighting the engineering efficiency of our water-centric business by linking it with the best water transportation of all â that which occurs in nature. For more information, please visit us at www.xylem.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181011005840/en/
For Xylem Inc.
Media
Laurie Leavy, +1-914-260-2626
[email protected]
or
Investors
Matthew
Latino, +1-914-323-5821
[email protected]
Source: Xylem Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- GPA Global Names Anne Marie Shulman to New Role Leading North American Luxury Packaging Growth
- Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study
- BrenX CEO Nir Brenmiller Featured on "The Big Biz Show"
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share